Exelixis clinical trials we track

Check company identity source

Phase 3 7 trials

TrialDrugs studiedStatusPrimary completion
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Abiraterone, Atezolizumab, Cabozantinib, Enzalutamide and 3 moreEnrolling by invitation2030-05-31Estimated
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673Nivolumab, Sunitinib Malate, XL092Active not recruiting2026-12-15Estimated
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940Atezolizumab, Regorafenib, XL092Active not recruiting2026-06-16Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117Abiraterone Acetate, Atezolizumab, Cabozantinib, Enzalutamide and 1 moreActive not recruiting2024-04-19Actual
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219Cabozantinib, Ipilimumab, NivolumabActive not recruiting2022-01-31Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791Atezolizumab, Cabozantinib, SorafenibActive not recruiting2021-11-30Actual
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388CabozantinibActive not recruiting2020-08-19Actual

Phase 2 / 3 2 trials

Phase 2 5 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184 Measure: In the Expansion Phase, to evaluate the efficacy of XL184 treatment. After: Measure: Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Measure: Expansion Phase: Objective Response Rate (ORR).

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Radiographic progression free survival (PFS). After: Measure: Radiographic Progression Free Survival (PFS).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) Measure: Duration of Overall Survival (OS). After: Measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) Measure: Duration of Overall Survival (OS).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm Measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm. After: Measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population Measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population.

Check registry source